How Biocon's Insulin Aspart, at Centre of ‘Bribery Controversy’, is Different from Its Peers It is alleged that a bribe was given to Central Drugs Standard Control Organisation (CDSCO)’s official to waive off the Phase 3 clinical trial of the medicine in India
